Previous 10 | Next 10 |
FNCB Bancorp Inc. (FNCB) is expected to report for Q1 2024 Civista Bancshares Inc. (CIVB) is expected to report $0.6 for Q3 2023 ASLAN Pharmaceuticals Limited (ASLN) is expected to report $-0.85 for Q3 2023 Grupo Televisa S.A. (TV) is expected to report $0.02 for Q3 2023 Red River...
ASLAN Pharmaceuticals Limited (ASLN) is expected to report $-0.85 for Q3 2023
Discussion featuring KOLs Dr Jonathan Silverberg, Dr April W. Armstrong, and a leading CRO will explore “The Changing Face of Atopic Dermatitis: How the Clinical Trial and Treatment Landscape Has Changed in the Seven Years Following Dupilumab’s Introduction” A...
ASLAN management will present emerging data from the TREK-AD study and new market research data on the AD treatment landscape from patient and prescriber surveys Register here to attend the webinar event on October 24, 2023 at 11:00 am ET SAN MATEO, Calif. and SINGAPOR...
Data presented during the late-breaker oral presentation of the TREK-AD study demonstrate e blasakimab’s potential as the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation Ne...
SAN MATEO, Calif. and SINGAPORE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that four abstracts on eblasakimab and ...
SAN MATEO, Calif. and SINGAPORE, Sept. 07, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will give an in-person comp...
2023-08-11 10:24:12 ET ASLAN Pharmaceuticals press release ( NASDAQ: ASLN ): Q2 GAAP EPS of -$0.93. As of June 30, 2023, the Company had cash and cash equivalents of $40.9 million. $12.0 million upfront strategic license payment from Zenyaku received in July, extending the...
Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab that met the primary endpoint across three dose arms with statistical significance. The data established eblasakimab , a potential first-in-class antibody, as the first biologic in...
2023-07-07 12:50:55 ET Gainers: Prestige Wealth ( PWM ) +90% . Castle Biosciences ( CSTL ) +52% . Near Intelligence ( NIR ) +44% . T2 Biosystems ( TTOO ) +37% . Greenidge Generation Holdings ( GREE ) +31% . The Real Good Food...
News, Short Squeeze, Breakout and More Instantly...
ASLAN Pharmaceuticals Limited Company Name:
ASLN Stock Symbol:
NASDAQ Market:
Positive interim data readout from 22 patients in TREK-DX study of eblasakimab showed unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab -experienced AD patients treated with 400mg eblasakimab weekly ...
New positive data from an additional analysis of dupilumab-experienced patients treated with eblasakimab 400mg, weekly over 16 weeks further supp...